Cloning of a T cell growth factor that interacts with the ? chain of the interleukin-2 receptor, Science, vol.264, pp.965-973, 1994. ,
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokineactivated killer cells, Proc Natl Acad Sci U S A, vol.91, pp.4935-4944, 1994. ,
,
, IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2, J Leukoc Biol, vol.57, pp.763-769, 1995.
Functional characterization of the human interleukin-15 receptor ? chain and close linkage of IL15RA and IL2RA genes, J Biol Chem, vol.270, pp.29862-29871, 1995. ,
Identification and cloning of a novel IL-15 binding protein that is structurally related to the ? chain of the IL-2 receptor, Embo J, vol.14, pp.3654-63, 1995. ,
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice, J Exp Med, vol.191, pp.771-80, 2000. ,
T cell-independent interleukin 15R? signals are required for bystander proliferation, J Exp Med, vol.194, pp.1187-94, 2001. ,
, RLI, an IL-15-IL-15R? Fusion Protein, Tumor Therapy Mol Cancer Ther, vol.8, issue.9, 2009.
IL-15 and IL-2: a matter of life and death for T cells in vivo, Nat Med, vol.7, pp.114-122, 2001. ,
Effective cancer therapy through immunomodulation, Annu Rev Med, vol.57, pp.65-81, 2006. ,
Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation, Cancer Gene Ther, vol.13, pp.969-74, 2006. ,
Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice, Cancer Immunol Immunother, vol.53, pp.363-72, 2004. ,
Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model, Oncol Rep, vol.19, pp.1173-1182, 2008. ,
Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma, Mol Ther, vol.8, pp.552-560, 2003. ,
The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement, J Immunol, vol.165, pp.3111-3119, 2000. ,
IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations, Cell Immunol, vol.179, pp.66-73, 1997. ,
Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis, Breast Cancer Res Treat, vol.114, pp.423-454, 2009. ,
Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model, Cancer Res, vol.58, pp.3270-3274, 1998. ,
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer, Cancer Res, vol.58, pp.1695-1704, 1998. ,
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T cells, Proc Natl Acad Sci U S A, vol.101, pp.1969-74, 2004. ,
Twelve immunotherapy drugs that could cure cancers, Immunol Rev, vol.222, pp.357-68, 2008. ,
Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15, Cancer Res, vol.60, pp.3577-83, 2000. ,
NK cells and cancer, J Immunol, vol.178, pp.4011-4017, 2007. ,
IL-15R? recycles and presents IL-15 in trans to neighboring cells, Immunity, vol.17, pp.537-584, 2002. ,
IL-15R? chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation, J Exp Med, vol.205, pp.1213-1238, 2008. ,
Converting IL-15 to a superagonist by binding to soluble IL-15R?, Proc Natl Acad Sci, vol.103, pp.9166-71, 2006. ,
Combined IL-15/IL-15R? immunotherapy maximizes IL-15 activity in vivo, J Immunol, vol.177, pp.6072-80, 2006. ,
Preassociation of IL-15 with IL-15R ?-IgG1-Fc enhances its activity on proliferation of NK and CD8 + /CD44 high T cells and its antitumor action, J Immunol, vol.180, pp.2099-106, 2008. ,
Interleukin-15/interleukin-15R? complexes promote destruction of established tumors by reviving tumor-resident CD8 + T cells, Cancer Res, vol.68, pp.2972-83, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-01602340
The exon-3-encoded domain of IL-15R? contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15R?, J Mol Biol, vol.382, pp.1-12, 2008. ,
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo, J Exp Med, vol.206, pp.25-34, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-02442774
Soluble interleukin-15 receptor ? (IL-15R?)-sushi as a selective and potent agonist of IL-15 action through IL-15R?/?. Hyperagonist IL-15 × IL-15R? fusion proteins, J Biol Chem, vol.281, pp.1612-1621, 2006. ,
Identification of an interleukin-15? receptor-binding site on human interleukin-15, J Biol Chem, vol.279, pp.24313-24335, 2004. ,
Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites, Am J Pathol, vol.170, pp.1077-85, 2007. ,
Subunit structure of the high and low affinity human interleukin-15 receptors, Eur Cytokine Netw, vol.11, pp.207-222, 2000. ,
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2, JAMA, vol.271, pp.907-920, 1994. ,
Vascular leak syndrome: a side effect of immunotherapy, Immunopharmacology, vol.37, pp.117-149, 1997. ,
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group, BMJ, vol.321, pp.531-536, 2000. ,
Managing toxicities of high-dose interleukin-2, Oncology (Williston Park), vol.16, pp.11-20, 2002. ,
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy, Immunity, vol.14, pp.105-115, 2001. ,
Inhibition of tumor growth by NK1.1 + cells and CD8 + T cells activated by IL-15 through receptor ?/common ? signaling in trans, J Immunol, vol.181, pp.8237-8284, 2008. ,
Cancer statistics, CA Cancer J Clin, vol.58, pp.71-96, 2008. ,
Systemic treatment of colorectal cancer, Gastroenterology, vol.134, pp.1296-310, 2008. ,
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, vol.343, pp.905-919, 2000. ,
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, vol.22, pp.23-30, 2004. ,